CurveBeam AI Limited (ASX:CVB): HiRise Imaging Advances Clinical Reach and China Market Access

Aditi Sarkar

16 October 2026 07:28 PM AEDT

CurveBeam AI Limited (ASX:CVB): HiRise Imaging Advances Clinical Reach and China Market Access

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

HiRise weight-bearing CT received regulatory approval in China in October 2026.
The company combines specialised orthopaedic imaging equipment with AI-enabled clinical assessment software.
Its June 2026 quarter included two HiRise purchase orders and A$2.58 million in customer receipts.
FY26 revenue declined from the prior year while operating cash outflows increased.
Commercial deployment, software adoption and funding remain central execution considerations.

CurveBeam AI Limited (ASX:CVB) develops and manufactures specialised point-of-care CT imaging equipment for musculoskeletal assessment, alongside AI-enabled software tools for clinicians. Its HiRise system captures three-dimensional images of extremities under weight-bearing conditions. During 2026, the company advanced its international distribution plans while reporting financial results that highlighted the costs of expanding a specialist medical imaging business.

HiRise Secures China Regulatory Clearance

China’s National Medical Products Administration approved the HiRise weight-bearing CT system in October 2026. CurveBeam AI Limited (ASX:CVB) announced the approval on 13 October, following a trading halt requested for the regulatory update. This represents an important distinction between obtaining permission to market a device and achieving commercial sales: the approval addresses a regulatory requirement, but does not itself establish hospital orders or recurring revenue.

CurveBeam AI Limited (ASX:CVB) had previously described agreements supporting commercialisation in China, Hong Kong, Macau and Taiwan. The company’s October announcement also identified a milestone-related A$1 million equity investment at A$0.405 per share. The timing and scale of customer deployments remain separate from those contractual and regulatory steps. As hospital purchasing processes differ by jurisdiction, sales execution and installation activity remain relevant measures of progress.

Why Weight-Bearing CT Matters

Conventional scanning approaches can assess anatomical structures without reproducing the loading conditions experienced while standing. HiRise is designed to obtain three-dimensional scans under weight-bearing conditions, which can provide additional anatomical information for orthopaedic evaluation and procedural planning. CurveBeam AI Limited (ASX:CVB) positions its equipment for point-of-care settings, bringing specialised imaging closer to clinicians handling foot, ankle and other musculoskeletal cases.

The company also offers AI-enabled clinical assessment software. Its commercial model therefore encompasses both physical equipment and related digital capabilities. These are distinct revenue opportunities: hardware demand depends on purchasing and installation decisions, while software utilisation depends on clinical integration, product functionality and customers’ ongoing requirements. No unsupported assumptions about software subscription uptake are necessary to assess the differences between these activities.

FY26 Results and Cash Use

In its FY26 annual report, CurveBeam AI Limited (ASX:CVB) recorded revenue of $8,666,146, compared with $12,096,583 in FY25. Net loss before tax was $18,831,356, against $16,842,748 a year earlier. Net cash used in operating activities rose to $13,014,681 from $11,169,588. These outcomes show that regulatory and product milestones occurred alongside reduced reported revenue and increased operating cash requirements.

Its quarter ended 30 June 2026 generated A$2.58 million in customer receipts, compared with A$1.43 million in the preceding quarter. CurveBeam AI Limited (ASX:CVB) reported two HiRise purchase orders for the June quarter. Customer receipts and purchase orders are useful operational indicators, but they are not interchangeable with recognised revenue, and individual quarters may not reflect the full-year pattern.

Execution Risks and Operational Priorities

Medical-device commercialisation involves manufacturing capacity, training, distribution support, reimbursement considerations and regulatory responsibilities. CurveBeam AI Limited (ASX:CVB) must also manage expenditure against its available funding while building customer adoption. Delays in system installations or customer purchasing decisions can affect the timing of receipts. Product approvals across different territories do not remove the need for local commercial execution.

Key Insights

The 2026 HiRise clearance in China adds a defined regulatory milestone to CurveBeam AI Limited (ASX:CVB)’s international imaging strategy. Its significance is best considered alongside actual equipment orders, customer receipts, installation activity and financial reporting. FY26 results demonstrate that clinical technology development and commercial rollout do not necessarily translate immediately into higher revenue or lower cash usage.

FAQs

Q: What does CurveBeam AI manufacture?

A:Specialised CT imaging systems for musculoskeletal assessment, supported by AI-enabled clinical assessment software.

Q: What was approved in China in October 2026?

A:The HiRise weight-bearing CT imaging system received approval from China’s NMPA.

Q: Did FY26 revenue increase?

A:No. Revenue was $8,666,146, compared with $12,096,583 in FY25.

Q: What were June-quarter customer receipts?

A:The company reported A$2.58 million for the quarter ended 30 June 2026.

Q: Does China approval guarantee sales?

A:No. Regulatory permission and commercial purchasing, installations and revenue recognition are separate steps.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.